Myriad Genetics, Inc. (NASDAQ:MYGN) VP Richard M. Marsh sold 13,759 shares of the business’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $36.25, for a total transaction of $498,763.75. Following the completion of the sale, the vice president now directly owns 136,385 shares of the company’s stock, valued at approximately $4,943,956.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Myriad Genetics, Inc. (NASDAQ MYGN) traded down $0.26 during mid-day trading on Tuesday, reaching $35.79. The company had a trading volume of 1,073,954 shares, compared to its average volume of 567,490. The firm has a market capitalization of $2,500.00, a P/E ratio of 24.18, a PEG ratio of 2.29 and a beta of 0.24. Myriad Genetics, Inc. has a fifty-two week low of $15.15 and a fifty-two week high of $37.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.05. The business had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. Myriad Genetics’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 earnings per share. analysts anticipate that Myriad Genetics, Inc. will post 1.05 EPS for the current fiscal year.

A number of brokerages have recently issued reports on MYGN. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 target price for the company in a research report on Tuesday, October 17th. Morgan Stanley reissued an “underweight” rating and issued a $24.00 target price (up previously from $17.00) on shares of Myriad Genetics in a research report on Friday, October 6th. Stephens reissued an “overweight” rating and issued a $40.00 target price (up previously from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued a “market perform” rating and issued a $31.00 target price on shares of Myriad Genetics in a research report on Monday, October 2nd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $30.09.

A number of hedge funds have recently bought and sold shares of the stock. CS Mckee LP raised its stake in Myriad Genetics by 0.3% in the second quarter. CS Mckee LP now owns 30,000 shares of the company’s stock valued at $775,000 after purchasing an additional 100 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in Myriad Genetics by 1.0% during the second quarter. Public Employees Retirement System of Ohio now owns 143,036 shares of the company’s stock worth $3,696,000 after acquiring an additional 1,480 shares in the last quarter. TrimTabs Asset Management LLC raised its stake in Myriad Genetics by 17.2% during the third quarter. TrimTabs Asset Management LLC now owns 11,798 shares of the company’s stock worth $427,000 after acquiring an additional 1,728 shares in the last quarter. Riverhead Capital Management LLC raised its stake in Myriad Genetics by 80.9% during the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock worth $107,000 after acquiring an additional 1,861 shares in the last quarter. Finally, Stifel Financial Corp raised its stake in Myriad Genetics by 3.6% during the third quarter. Stifel Financial Corp now owns 54,408 shares of the company’s stock worth $1,968,000 after acquiring an additional 1,900 shares in the last quarter.

WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/16/myriad-genetics-inc-mygn-vp-sells-498763-75-in-stock.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.